All Stories

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

On track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion.

Mar 12, 2025 - 19:21
 0
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
On track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion.
Read More

Tags:

Previous Article

Argenx’s Vyvgart tops Trinity’s latest launch success analysis, beating out seve...

Next Article

Balance of power: Loch Ness hydro storage schemes fuel local anxiety

Related Posts

Regulatory tracker: Eisai's Alzheimer's drug Leqembi rejected in Australia

Regulatory tracker: Eisai's Alzheimer's drug Leqembi re...

Mar 3, 2025  0

Abbott's stigma-busting campaign shows how diabetes biases lead to silence, skipped care

Abbott's stigma-busting campaign shows how diabetes bia...

Feb 21, 2025  0

Leerink group goes beyond conventional metrics to evaluate cost-effectiveness of key therapies

Leerink group goes beyond conventional metrics to evalu...

Feb 18, 2025  0